gilead sciences hiv - Search News

News

FDA Approves Gilead’s HIV Shot. It Works 99.9% of Time.

USA TODAY on MSN · 2h

FDA approves new twice-yearly HIV shot. What to know

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

PharmExec · 47m

FDA Approves Gilead’s Yeztugo as First Twice-Yearly Injection for HIV Pre-Exposure Prophylaxis

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 trials, which show that ≥99.9% of patients treated with Yeztugo remained HIV-negative.

Barron's on MSN · 23h

FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who received it in large clinical trials. The drug, developed by Gilead Sciences and called Yeztugo,

Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access?

Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...

1d

Should You Buy Gilead Stock At $110?

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award

Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results